Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of...

24
Ezetimibe: • Ook hiermee reductie van events van een niet-statine middels LDL daling • Improve-It • Ook ondersteuning door Mendelian Randomization studies

Transcript of Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of...

Page 1: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).

Ezetimibe:

•  Ook hiermee reductie van events van een niet-statine middels LDL daling

•  Improve-It •  Ook ondersteuning door Mendelian Randomization

studies

Page 2: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 3: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).

NEJM 2015

Page 4: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 5: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 6: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).

NEJM 2006

LDL 100 mg/dl = 2.5 mmol/l

Page 7: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 8: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 9: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 10: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 11: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 12: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).

ACC 2015

Page 13: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).

Improve-It: externe validiteit

•  Middel is effectief en veilig …. •  Enge interpretatie: alleen tbv streven naar zeer lage

LDL waarden post ACS.. •  Ruime interpretatie: te gebruiken naast max

getolereerde statine therapie bij streven naar voldoende LDL daling cq streven naar LDL doelwaarde ..

•  Immers: rosuva ook te gebruiken buiten prim preventie populatie met licht verhoogd CRP ….

Page 14: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).

Dus visie tav ezetimibe:

•  Genetisch gevalideerd •  Externe validiteit •  Ook incorporatie in toekomstige adviezen tav PCSK9

Page 15: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 16: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 17: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 18: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).

Nb: LDL daling .. het hoe is ook van belang !!

Page 19: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 20: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 21: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 22: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).
Page 23: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).

PCSK9:

•  Alles wijst op een succesvolle uitkomst van de studies •  Genetisch gevalideerd •  Safety zal zelden in een RCT goed tot uiting komen •  Primair inzetten bij patiënten met een zeer hoog

residueel risico (maar denk tegelijkertijd aan andere medicatie .. langer geven van DAPT etc)..

•  Game-changer: vergelijkbaar met introductie van NOACs bij AF

Page 24: Ezetimibe - CVGKACC 2015 . Improve-It: externe validiteit ... alter the splicing process at sites of modification of the nascent pre—mes- senger RNA transcript (splice-site mutations).

Josephine Senger

Josephine Senger

Original Article Combination of Statin and Ezetimibe ...

Original Article Combination of Statin and Ezetimibe ...

Pharmaceutical Benefits Scheme (PBS) | Home - Abbreviationspbs.gov.au/reviews/ezetimibe-review-files/draft... · Web viewPharmaceutical Benefits Scheme Post-market Review Ezetimibe

Pharmaceutical Benefits Scheme (PBS) | Home - Abbreviationspbs.gov.au/reviews/ezetimibe-review-files/draft... · Web viewPharmaceutical Benefits Scheme Post-market Review Ezetimibe

Validiteit en betrouwbaarheid van de Nederlandse Triage ...

Validiteit en betrouwbaarheid van de Nederlandse Triage ...

Merck Sharp & Dohme Corp. VYTORIN- ezetimibe and ...

Merck Sharp & Dohme Corp. VYTORIN- ezetimibe and ...

Product Information for Ezetrol (ezetimibe)€¦ · Attachment 1: Product information for Ezetrol Ezetimibe Merck AusPAR Sharpe and Dohme (Australia) Pty Limited PM-2011-01220-3-3

Product Information for Ezetrol (ezetimibe)€¦ · Attachment 1: Product information for Ezetrol Ezetimibe Merck AusPAR Sharpe and Dohme (Australia) Pty Limited PM-2011-01220-3-3

Public Assessment Report Scientific discussion Ezetimibe ...

Public Assessment Report Scientific discussion Ezetimibe ...

Ezetimibe and in Aortic Stenosis

Ezetimibe and in Aortic Stenosis

Effects of ezetimibe/simvastatin 10/10 mg versus ...

Effects of ezetimibe/simvastatin 10/10 mg versus ...

Peter Senger (GSI)

Peter Senger (GSI)

High-dose or low dose statin, with ezetimibe or without ezetimibe: … · 2016-06-16 · Colin Baigent Professor of Epidemiology Disclosure of potential conflicts of interest Research

High-dose or low dose statin, with ezetimibe or without ezetimibe: … · 2016-06-16 · Colin Baigent Professor of Epidemiology Disclosure of potential conflicts of interest Research

Effects of ezetimibe, a new cholesterol absorption inhibitor, on

Effects of ezetimibe, a new cholesterol absorption inhibitor, on

Presented by April Senger Chapter 30 Minerals & Their Formation.

Presented by April Senger Chapter 30 Minerals & Their Formation.

PRODUCT MONOGRAPH - Sandoz Product... · Sandoz Ezetimibe Page 5 of 30 Patients with Liver Impairment: The pharmacokinetics of ezetimibe were examined in patients with impaired liver

PRODUCT MONOGRAPH - Sandoz Product... · Sandoz Ezetimibe Page 5 of 30 Patients with Liver Impairment: The pharmacokinetics of ezetimibe were examined in patients with impaired liver

Formulation and Evaluation of Ezetimibe Nanoparticles

Formulation and Evaluation of Ezetimibe Nanoparticles

Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia

Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia

Senger the Idea of Change

Senger the Idea of Change

Comparative Efficacy of Ezetimibe/simvastatin ...

Comparative Efficacy of Ezetimibe/simvastatin ...

The Resurrection of Ezetimibe: A Story of Perseverance · 1 The Resurrection of Ezetimibe: A Story of Perseverance Harry “Chip” Davis CVPath Institute Gaithersburg, MD (Schering-Plough

The Resurrection of Ezetimibe: A Story of Perseverance · 1 The Resurrection of Ezetimibe: A Story of Perseverance Harry “Chip” Davis CVPath Institute Gaithersburg, MD (Schering-Plough

Public Assessment Report Scientific discussion Rosuvastatine/Ezetimibe Fontane … · 2019-10-23 · Public Assessment Report Scientific discussion Rosuvastatine/Ezetimibe Fontane

Public Assessment Report Scientific discussion Rosuvastatine/Ezetimibe Fontane … · 2019-10-23 · Public Assessment Report Scientific discussion Rosuvastatine/Ezetimibe Fontane